• Home
  • About Us
    • IOCN Policies & Governance
    • Disclaimer and Conditions of Use Policy
  • Clinical Support
    • IO Toxicity Guidelines
    • IOCN Consensus Statements
    • MDT
    • Specialist Support
    • Case Series
    • Patient Information
    • Consent Forms
    • Video Resources
      • Videos for Patients
    • Immunobuddies Patient Information
    • IO Cardiac Complications
  • Education & Training
    • National IO Education Forum
    • Case of the Month
    • Education Ethos
    • Educational Events
    • Immunobuddies Podcast
  • Policy & Governance
  • Research & Analysis
    • Translational Research
  • Service Development
  • Join Us
enquiries@ioclinicalnetwork.co.uk

@IOClinicalNet

  • Home
  • About Us
  • Clinical Support
  • Education & Training
  • Policy & Governance
  • Research & Analysis
  • Service Development
  • Join Us

IOCN

The Immuno-Oncology Clinical Network

ICI induced Cardiovascular complications 

Cardiovascular risk assessment and baseline biomarkers

  • 2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS).

  • IOCN and BCOS 'Baseline Cardiac Biomarker Consensus Statement'

Myocarditis diagnosis, investigation and management:

  • The Clatterbridge Cancer Centre Myocarditis Guideline 
  • ESMO Management of toxicities from Immunotherapy 

ECG features and monitoring in suspected myocarditis:

  • Electrocardiographic Manifestations of Immune Checkpoint Inhibitor Myocarditis

  • Electrocardiographic features of immune checkpoint inhibitor associated myocarditis

    Registered Charity In England and Wales

    Charitable Number: 1205140

    Join Us: Become a Member of the IOCN

    IOCN Disclaimer and Conditions of User Policy